Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 14, 2012; 18(38): 5427-5433
Published online Oct 14, 2012. doi: 10.3748/wjg.v18.i38.5427
Published online Oct 14, 2012. doi: 10.3748/wjg.v18.i38.5427
Table 1 Clinical characteristics of patients with life-threatening severe anaphylactic reactions following oxaliplatin chemotherapy (n = 8)
Patient | Sex | Age (yr) | Allergy history | Primary CRC site | TNM classification | Stage | Previous chemotherapy regimens | Previous oxaliplatin chemotherapy cycles | Oxaliplatin dose (mg/m2) | Tumor response | Presenting symptoms | Onset time | Outcome | Rechallenge |
1 | F | 50 | Alcohol | Rectum | T4N0M1 | IV | FOLFIRI x12, FOLFOX x10 | 10 | 85 | SD | Consciousness loss, dizziness, shock | 30 min | Recovery | No |
2 | M | 71 | Nil | Rectum | T2N1M1 | IV | FOLFOX x12, FOLFIRI + Bevacizumabx12, FOLFOX x1 | 13 | 85 | PD | Consciousness loss, shock | 20 min | Fatal | No |
3 | M | 36 | Nil | Sigmoid colon | T4N2M1 | IV | FOLFIRI x13, FOLFOX + Bevacizumab x5, FOLFIRI + Cetuximab x5, FOLFOX x7 | 12 | 90 | PD | Consciousness loss, respiratory distress, cold sweating | Immediate | Recovery | Yes |
4 | F | 57 | Nil | Sigmoid colon | T1N0M1 | IV | FOLFIRI x5, FOLFOX x7, FOLFIRI + Bevacizumabx18, FOLFOX + Bevacizumab x1 | 8 | 85 | PD | Respiratory distress, cold sweating | 2 h | Recovery | No |
5 | F | 68 | Nil | Sigmoid colon | T3N2M1 | IV | FOLFIRI x12, FOLFOX x8 | 8 | 85 | SD | Angioedema, slurred speech, respiratory distress | 30 m | Recovery | No |
6 | F | 72 | Nil | Descending colon | T4N1M1 | IV | FOLFIRI x7, FOLFOX x3, FOLFIRI x12, FOLFOX x2 | 5 | 85 | PD | Nausea, vomiting, shock, | 10 min | Recovery | No |
7 | M | 59 | Flurbiprofen | Rectum | T3N2M1 | IV | FOLFOX x19, FOLFIRI x8, FOLFOX x10 | 29 | 85 | SD | Consciousness loss, respiratory distress, cold sweating | Immediate | Recovery | No |
8 | M | 62 | Nil | Sigmoid colon | T3N1M1 | IV | FOLFIRI + Bevacizumabx6, FOLFOX x7 | 7 | 85 | PD | Consciousness loss, respiratory distress, cold sweating | 20 min | Recovery | No |
Table 2 Studies on severe anaphylactic reactions following oxaliplatin, including data published from 1997 to 2012 in English (24 studies, n = 66)
Ref. | Published year/region | Patient No. | Age (yr) | Male/female | Previous oxaliplatin cycles | Oxaliplatin dose (mg/m2) | Presenting symptoms | Onset time after oxaliplatin infusion | Outcome |
de Gramont et al[10] | 1997/France | 5 | NA | NA | NA | NA | NA | NA | Recovery |
Tournigand et al[11] | 1998/France | 5 | 59-77 | 3/2 | 5-12 | 85-100 | Reduced blood pressure, flushing, headache, tachycardia, respiratory distress | Immediate | Recovery |
Larzillière et al[12] | 1999/France | 1 | 55 | 1/0 | 5 | 85 | Flushing, profuse sweats, arterial hypertension, tachycardia | 30 min | Recovery |
Médioni et al[13] | 1999/France | 1 | 63 | 1/0 | 6 | 100 | Visual disturbances, edema, tachycardia, severe hypotension, anaphylactic shock | Immediate | Recovery |
Sørbye et al[14] | 2000/Norway | 1 | 40, 52 | 1/0 | 8 | 85 | Severe thrombocytopenia | Immediate | Recovery |
Santini et al[15] | 2001/Italy | 1 | 52 | 1/0 | 6 | 60 | Chills, fever, nausea, vomiting, crampy abdominal pain, diarrhea, hypotension | 15 min | Recovery |
Schüll et al[16] | 2001/Austria | 1 | 54 | 1/0 | 5 | 85 | Flush, generalised erythema of the trunk, nausea, hypotension | 30 min | Recovery |
Brandi et al[17] | 2003/Italy | 9 | NA | NA | 2-17 | NA | Dyspnea, laryngospasm, agitation, tachycardia, precordial pain, erythema, sweating | NA | Recovery |
Thomas et al[18] | 2003/United States | 1 | 50 | 0/1 | 9 | NA | Fever, respiratory distress | 2 h | Recovery |
Lenz et al[19] | 2003/Germany | 2 | NA | NA | NA | 85 | Severe abdominal, chest pain. | Immediate | Recovery |
Bhargava et al[20] | 2004/United States | 1 | 50 | 0/1 | 12 | NA | Palpitation, flushing, hypotensive, wheezing | 15 min | Recovery |
González-Mahave et al[21] | 2005/Spain | 2 | 43, 44 | 1/1 | 4, 11 | NA | Respiratory collapse, fever | Immediate | Recovery |
Maindrault-Goebel et al[22] | 2005/France | 3 | NA | NA | NA | NA | Anaphylactic shock | NA | Recovery |
Siu et al[8] | 2006/Hong Kong | 2 | NA | NA | NA | 100 | Hypotension, oxygen desaturatio, full-blown anaphylactic reactions | NA | NA |
Tze et al[23] | 2006/China | 1 | 60 | 0/1 | 12 | NA | Anaphylactic shock | Immediate | Recovery |
Lee et al[24] | 2006/Taiwan | 4 | 36-74 | NA | 6-7 | 85-100 | Anaphylactic shock, hypertensive crisis | 5-50 min | Recovery |
Yanqi et al[25] | 2007/China | 1 | 52 | 1/0 | 6 | 150 mg | Anaphylactic shock | 10 min | Recovery |
Santodirocco et al[26] | 2008/Italy | 1 | 44 | 0/1 | 14 | 85 | Acute thrombocytopenia, hemolysis, bleeding | 1 h | Recovery |
Shao et al[27] | 2008/Taiwan | 1 | 64 | 1/0 | 23 | NA | Thrombocytopenia | 1 h | Fatal |
Chay et al[9] | 2010/Singapore | 11 | 36-75 | 4/7 | NA | NA | Respiratory collapse, flushing, hypokalemia | NA | Recovery |
Pietrantonio et al[28] | 2010/Italy | 1 | NA | NA | NA | NA | Acute thrombocytopenia | NA | Recovery |
Potenza et al[29] | 2010/Italy | 1 | 46 | 1/0 | 6 | 85 | Respiratory collapse | 10 h | Recovery |
Teng et al[30] | 2011/Taiwan | 1 | 78 | 1/0 | 17 | 85 | Pancytopenia, coagulopathy, intracranial hemorrhage | 30 min | Fatal |
Wang et al, this study | 2012/Taiwan | 7 | 36-72 | 3/4 | 5-29 | 85-90 | Consciousness loss, chest tightness, cold sweating, nausea, vomiting, shock | immediately to 2 h | 1 fatal |
- Citation: Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: Case series analysis. World J Gastroenterol 2012; 18(38): 5427-5433
- URL: https://www.wjgnet.com/1007-9327/full/v18/i38/5427.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i38.5427